The initiation of the Phase 2a study for VTX3232 in Parkinson’s disease is promising, with initial data expected in the first half of 2025. However, the limited size of this study, involving only 10 ...
Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback